polyclonal rabbit anti human myd88  (Boster Bio)

Journal: Diabetology & Metabolic Syndrome

Article Title: High glucose induces and activates Toll-like receptor 4 in endothelial cells of diabetic retinopathy

doi: 10.1186/s13098-015-0086-4

Figure Lengend Snippet: Activation of MyD88 and cytokine expression in HMEC-1 cells under high glucose condition. a Western blotting was performed for MyD88 expression in the HMEC-1 cells after exposure to 15 and 25 mmol/l glucose for 12 h. β-actin was used as a control. b Cells were treated with 15 and 25 mmol/l glucose for 6 h. The mRNA for IL-1β was detected by quantitative RT-PCR and normalized to GAPDH. Asterisk indicates P < 0.05 compared to 5.5 mmol/l glucose. c The cells were stimulated with 15 mmol/l glucose for 0, 1, 3, 6, 12 and 24 h. The mRNA of IL-1β was detected by quantitative RT-PCR and normalized to GAPDH to the 0 h group and expressed as the mean ± SE. * P < 0.05 compared to the 0 h group. d IL-1β protein in the supernatants of HMEC-1 cells after high-glucose treatment for indicated time points measured using ELISA. Asterisk indicates P < 0.05 compared to 5.5 mmol/l glucose

Article Snippet: After being blocked with 5 % nonfat milk for 1 h, the membrane were incubated with the following primary antibodies at 4 °C overnight: polyclonal rabbit anti-human TLR4 (1:500; Boster Wuhan, China), polyclonal rabbit anti-human MyD88 (1:100; Boster Wuhan, China) and monoclonal mouse anti-β-actin (1:100; Boster, Wuhan, China).

Techniques: Activation Assay, Expressing, Western Blot, Control, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay

Journal: Oncology Letters

Article Title: TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma in vitro

doi: 10.3892/ol.2013.1759

Figure Lengend Snippet: Results for TLR4 and MyD88 expression in tissues.

Article Snippet: Sections were washed with PBS and incubated overnight at 4°C with polyclonal rabbit anti-human TLR4 antibody (1:50) or with polyclonal rabbit anti-human MyD88 (1:50; Santa Cruz Biotechnology, Inc.).

Techniques: Expressing

Journal: Oncology Letters

Article Title: TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma in vitro

doi: 10.3892/ol.2013.1759

Figure Lengend Snippet: Expression of TLR4 and MyD88 in EOC cells at the mRNA level. TLR4 was expressed in all EOC cell lines; however, positive expression of MyD88 was identified in SKOV3 and OVCAR3 cells, while negative MyD88 expression was observed in A2780 and 3AO cells. TLR4, Toll-like receptor 4; MyD88, myeloid differentiation factor 88; EOC, epithelial ovarian cancer.

Article Snippet: Sections were washed with PBS and incubated overnight at 4°C with polyclonal rabbit anti-human TLR4 antibody (1:50) or with polyclonal rabbit anti-human MyD88 (1:50; Santa Cruz Biotechnology, Inc.).

Techniques: Expressing

Journal: Oncology Letters

Article Title: TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma in vitro

doi: 10.3892/ol.2013.1759

Figure Lengend Snippet: Following TLR4 knockdown, the apoptotic response of Pac (2 μM) treatment in MyD88 + and MyD88 − EOC cell lines was investigated. EOC cell lines were treated with 2 μmol/l Pac for 24 h and the levels of caspase-3/7 were measured using the Caspase-Glo 3/7 assay. Data are presented as the mean ± SD from at least three independent experiments. A significant increase was identified in caspase-3/7 activity following Pac treatment in SKOV3/shTLR4 cells compared with SKOV3 and SKOV3/shControl cells, as was the case with the OVCAR3 cells. * P<0.001, vs. wt/Pac and shControl/Pac. TLR4, Toll-like receptor 4; MyD88, myeloid differentiation factor 88; EOC, epithelial ovarian cancer; Pac, paclitaxel; wt/Pac, SKOV3/OVCAR3/A2780/3AO parental cells treated with Pac; shControl/Pac, SKOV3/OVCAR3/A2780/3AO shControl cells treated with Pac; shTLR4/Pac, SKOV3/OVCAR3/A2780/3AO shTLR4 cells treated with Pac.

Article Snippet: Sections were washed with PBS and incubated overnight at 4°C with polyclonal rabbit anti-human TLR4 antibody (1:50) or with polyclonal rabbit anti-human MyD88 (1:50; Santa Cruz Biotechnology, Inc.).

Techniques: Knockdown, Caspase-Glo Assay, Activity Assay

Journal: Oncogene

Article Title: TLR4 signaling induced by lipopolysacharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer

doi: 10.1038/onc.2009.289

Figure Lengend Snippet: Expression of TLR4 and MyD88 in ovarian cancer, benign tumors and normal controls a

Article Snippet: Tumor cells deposited on glass slides were fixed in 2% (w/v) paraformaldehyde in PBS for 15 min, permeablized with 0.1% (w/v) Triton X in PBS, washed and blocked with 2% (w/v) bovine serum albumin (BSA; Sigma) in PBS for 4 min. Polyclonal goat anti-human TLR4 antibodies (Abs) (Santa Cruz Biotechnology; 1:100) or polyclonal rabbit anti-human MyD88 Abs (Cell Signaling Technology; 1:100) served as primary reagents.

Techniques: Expressing

Journal: Oncogene

Article Title: TLR4 signaling induced by lipopolysacharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer

doi: 10.1038/onc.2009.289

Figure Lengend Snippet: A ) Immunostaining for TLR4 in a normal ovarian tissue adjacent to tumor (1), benign tumor (2), borderline tumor (3) and ovarian cancer ( Adenocarcionoma serosum FIGO III) (4) (Mag. × 200, Inset × 600); Immunostaining for MyD88 in ovarian tissues adjacent to tumor (5), benign tumor (6), borderline tumor (7), ovarian cancer ( Adenocarcionoma serosum FIGO III) (8) (Mag. × 200, Inset × 600. B ) Immunofluorescence for TLR4 protein in an ovarian cancer cell line (SKOV3) (2) Negative staining for TLR4 using isotype control IgG (1). Immunofluorescence for MyD88 in ovarian carcinoma cell lines, SKOV3 (3) and A2780 (4) (× 400); C ) Expression of TLR4 mRNA and Western blot for TLR4 and MyD88 in ovarian cancer cell lines.

Article Snippet: Tumor cells deposited on glass slides were fixed in 2% (w/v) paraformaldehyde in PBS for 15 min, permeablized with 0.1% (w/v) Triton X in PBS, washed and blocked with 2% (w/v) bovine serum albumin (BSA; Sigma) in PBS for 4 min. Polyclonal goat anti-human TLR4 antibodies (Abs) (Santa Cruz Biotechnology; 1:100) or polyclonal rabbit anti-human MyD88 Abs (Cell Signaling Technology; 1:100) served as primary reagents.

Techniques: Immunostaining, Immunofluorescence, Negative Staining, Control, Expressing, Western Blot